All In Biotech

Drug Trial Radar · NCT05158699

Effectiveness of Periocular Drug Injection in CATaract Surgery

The ESCRS EPICAT Study: Effectiveness of Periocular Drug Injection in CATaract Surgery

Last checked: Nov 20, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 628 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

628

Actual

Start

Oct 13, 2021

Primary completion

Aug 13, 2024

Study completion Aug 13, 2024

Sponsor

Lead sponsor
Luigi RondasAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Society of Cataract and Refractive Surgeons
First posted
Dec 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (care provider, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cystoid macular edema (CME) is a major cause of suboptimal postoperative visual acuity after cataract surgery. Topical steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs) are used to prevent CME. However, noncompliance with eye drops may compromise the effectiveness of treatment. Dropless periocular drug delivery during cataract surgery may improve the outcomes and cost-effectiveness of cataract surgery, and may alleviate the burden on homecare organizations.

Conditions

  • Macular Edema
  • Cystoid Macular Edema
  • Retinal Disease
  • Cataract
  • Lens Diseases
  • Eye Diseases

Interventions

  • BromfenacDrug

    Bromfenac topical eye drops (Yellox)

  • DexamethasoneDrug

    Dexamethasone topical eye drops

  • Triamcinolone AcetonideDrug

    0.25ml of 40mg/ml (10mg) triamcinolone acetonide (Triesence/Vistrec) will be injected subconjunctivally

  • Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular SolutionDrug

    Omidria is added to the irrigation fluid used during cataract surgery. At the end of surgery, the anterior chamber will be filled with the ketorolac solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in central subfield mean macular thickness as a measurement of efficacyTime frame: Baseline, 6 weeks postoperatively

Locations

10 sites in 4 countries. Site status is shown where the registry gives one.

  • Hospital of the Brothers of Saint John of God

    Vienna, Austria

  • Vienna Institute for Research in Ocular Surgery, Hanusch Krankenhaus

    Vienna, Austria

  • Goethe University

    Frankfurt am Main, Germany

  • Amphia

    Breda, Netherlands

  • Deventer Ziekenhuis

    Deventer, Netherlands

  • Zuyderland Medisch Centrum

    Heerlen, Netherlands

  • University Eye Clinic Maastricht UMC+

    Maastricht, Netherlands

  • Canisius Wilhelmina Ziekenhuis Nijmegen

    Nijmegen, Netherlands

  • Elisabeth-Twee Steden Ziekenhuis, locatie Elisabeth

    Tilburg, Netherlands

  • University Hospital Coimbra

    Coimbra, Portugal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.